Global Hereditary Angioedema (HAE) Markets, 2017-2018 & 2019-2026

DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Hereditary Angioedema (HAE)" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This Market Spotlight report covers the Hereditary Angioedema market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts

Key Takeaways

    --  The report estimates that in 2017, there were approximately 402,700
        prevalent cases of hereditary angioedema worldwide, and forecasts that
        number to increase to 440,600 prevalent cases by 2026.
    --  The approved drugs in the hereditary angioedema space target complement
        proteins, androgen receptors, follicle-stimulating hormone,
        gonadotropin-releasing hormone, progesterone receptor, bradykinin B2
        receptor, and the kinin-kallikrein system. These are commonly
        administered via the intravenous or subcutaneous routes, with one
        product being available in an oral formulation.
    --  There are only seven drugs in active clinical development for hereditary
        angioedema, with five drugs in Phase I and two in Phase III.
    --  Therapies in mid-to-late-stage development for hereditary angioedema
        focus on targets such as the kinin-kallikrein system and complement
        proteins. These drugs are administered via the subcutaneous and oral
        routes.
    --  High-impact upcoming events for drugs in the hereditary angioedema space
        comprise topline Phase III trial results for BCX7353, topline Phase II
        trial results for KVD900, and a data exclusivity expiration for
        Ruconest.
    --  The overall likelihood of approval of a Phase I
        autoimmune/immunology-other asset is 20.7%, and the average probability
        a drug advances from Phase III is 69.4%. Drugs, on average, take 9.7
        years from Phase I to approval, compared to 8.7 years in the overall
        autoimmune/immunology space.
    --  There have been only three licensing and asset acquisition deals
        involving hereditary angioedema drugs during 2014-19. The $125m
        licensing agreement signed in 2016 between Pharming and Bausch Health,
        for the acquisition of North American commercialization rights for
        Ruconest, was the largest deal during the period.
    --  The distribution of clinical trials across Phase I-IV indicates that the
        majority of trials for hereditary angioedema have been in the late
        phases of development, with 55% of trials in Phase III-IV, and 45% in
        Phase I-II.
    --  The US has a substantial lead in the number of hereditary angioedema
        clinical trials globally. The UK leads the major EU markets, while
        Israel has the top spot in Asia.
    --  Clinical trial activity in the hereditary angioedema space is dominated
        by completed trials. Takeda has the highest number of completed trials
        for hereditary angioedema, with 25 trials.
    --  Takeda leads industry sponsors with the highest number of clinical
        trials for hereditary angioedema, followed by BioCryst.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
Subtypes

TREATMENT
C1-INH concentrates
Plasma-derived C1-INH (pdC1-INH)
Recombinant C1-INH (rhC1-INH)
Kallikrein inhibitor
Bradykinin receptor antagonist

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
BCX7353 for Hereditary Angioedema (September 4, 2018)
Cinryze (SQ) for Hereditary Angioedema (September 11, 2017)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
Takhzyro Among Hopefuls For EU Approval Recommendation
Takhzyro Approved For HAE Attacks With Nearly Spotless Label
With Takhzyro Approval, Shire Could Reclaim HAE Prophylaxis Market From CSL Behring

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
BioCryst Changes Mind On Idera Merger

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events

BIBLIOGRAPHY
Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/5qwslm

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


View original content:http://www.prnewswire.com/news-releases/global-hereditary-angioedema-hae-markets-2017-2018--2019-2026-300871246.html

SOURCE Research and Markets